List of Excipients in Branded Drug BREXAFEMME

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SCYNEXIS INC	BREXAFEMME	ibrexafungerp	75788-115	BUTYLATED HYDROXYANISOLE	2031-06-01
SCYNEXIS INC	BREXAFEMME	ibrexafungerp	75788-115	CELLULOSE, MICROCRYSTALLINE	2031-06-01
SCYNEXIS INC	BREXAFEMME	ibrexafungerp	75788-115	CROSPOVIDONE	2031-06-01
SCYNEXIS INC	BREXAFEMME	ibrexafungerp	75788-115	FD&C BLUE NO. 2	2031-06-01
SCYNEXIS INC	BREXAFEMME	ibrexafungerp	75788-115	FD&C RED NO. 40	2031-06-01
SCYNEXIS INC	BREXAFEMME	ibrexafungerp	75788-115	HYDROXYPROPYL CELLULOSE	2031-06-01
SCYNEXIS INC	BREXAFEMME	ibrexafungerp	75788-115	MAGNESIUM STEARATE	2031-06-01

Brexafemme Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Brexafemme, containing ibrexafungerp, is an oral triterpenoid antifungal marketed by SCYNEXIS for vulvovaginal candidiasis and reduction of recurrent vulvovaginal candidiasis. Its commercial opportunity is concentrated in lifecycle improvements that reduce food dependence, improve gastrointestinal tolerability, support repeat use, and extend the product into patient groups where oral dosing is difficult. The current tablet already has a relatively conventional excipient platform, which leaves room for differentiated formulations if the sponsor can demonstrate a clinically meaningful pharmacokinetic or adherence benefit.

What is Brexafemme and how is it administered?

Brexafemme is a prescription oral tablet containing 150 mg of ibrexafungerp. The FDA-approved regimen differs by indication:

Indication	FDA-approved regimen
Vulvovaginal candidiasis	300 mg orally, administered as two 150 mg tablets, approximately 12 hours apart
Reduction of recurrent vulvovaginal candidiasis	300 mg orally, administered as two 150 mg tablets, approximately 12 hours apart, once monthly for six months

Patients take Brexafemme with food. The product is supplied as an immediate-release oral tablet rather than a capsule, suspension, vaginal dosage form, or long-acting product. The label identifies inactive ingredients including microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide, hypromellose, talc, and film-coating components. Formulation composition should be evaluated against the latest FDA-approved prescribing information before development decisions are made. (U.S. Food and Drug Administration [FDA], 2024a)

Ibrexafungerp has a mechanism distinct from azole antifungals. It inhibits glucan synthase and has activity against Candida species, including strains with reduced susceptibility to azoles. That profile supports positioning in patients with recurrent disease, prior azole exposure, or treatment limitations related to resistance.

What excipient properties matter most for ibrexafungerp?

The highest-value excipient objectives are exposure control, food-effect reduction, tablet robustness, and gastrointestinal tolerability.

Solubility and absorption

Ibrexafungerp is a lipophilic small molecule with limited aqueous solubility. The current requirement to administer Brexafemme with food indicates that formulation and fed-state physiology affect systemic exposure. A formulation that produces equivalent exposure under fasted and fed conditions could reduce administration complexity and improve adherence.

Potential approaches include:

• Amorphous solid dispersions using polymeric carriers
• Surfactant-assisted wetting systems
• Lipid-based self-emulsifying systems
• Nanocrystalline or particle-size-reduced ibrexafungerp
• Spray-dried dispersions
• Co-processed excipient systems
• Supersaturating formulations with precipitation inhibitors

The commercial value of these approaches depends on whether they provide clinically relevant advantages without increasing tablet size, manufacturing complexity, or dose variability.

Gastrointestinal tolerability

Monthly repeat dosing creates a strong rationale for excipient work focused on nausea, abdominal discomfort, and tablet burden. The most useful formulation would maintain exposure while reducing local irritation or peak-related adverse effects.

Relevant excipient levers include:

• Controlled wetting rather than rapid dissolution
• Modified disintegration profiles
• Lower surfactant loading
• Polymer selection that reduces precipitation and sharp concentration peaks
• Multiparticulate delivery to distribute drug release in the gastrointestinal tract

A lower-peak formulation could be commercially meaningful if it preserves antifungal efficacy and avoids a material increase in total exposure.

Tablet size and dose burden

The standard regimen requires two 150 mg tablets per treatment day. A 300 mg unit-dose tablet could reduce pill burden, but the feasibility depends on ibrexafungerp loading, blend flow, compaction, dissolution, and tablet dimensions.

A 300 mg tablet would have the clearest value in recurrent vulvovaginal candidiasis, where treatment repeats monthly. The product could be positioned as a unit-dose therapy with simplified packaging and fewer administration errors.

What formulation patents could protect a Brexafemme lifecycle product?

A differentiated formulation could create patentable subject matter in several areas:

Protection area	Potential claim focus	Commercial purpose
Solid dispersion	Ibrexafungerp with a defined polymer, drug load, and solid-state profile	Improve dissolution and exposure
Particle engineering	Nanoparticles, micronized drug, or defined particle-size distribution	Increase dissolution rate
Lipid system	Specific oils, surfactants, co-solvents, and ratios	Reduce food dependence
Controlled release	Matrix or multiparticulate system with defined release profile	Reduce peak exposure or dosing burden
Unit-dose tablet	300 mg tablet with specified hardness, disintegration, and dissolution	Reduce pill burden
Taste or swallowability	Coating, granulation, or alternative dosage form	Support patient acceptance
Combination product	Ibrexafungerp with an approved adjunctive excipient or active agent	Differentiate treatment or prevention
Manufacturing process	Granulation, drying, milling, or coating process	Protect scale-up and quality attributes

The strongest formulation patent would link composition to a measurable clinical or biopharmaceutical result, such as fasted-state bioequivalence to the approved fed-state exposure, reduced pharmacokinetic variability, or comparable exposure at a lower dose.

A patent directed only to a routine excipient substitution is more vulnerable to obviousness challenges. A patent supported by comparative dissolution, animal pharmacokinetic, human pharmacokinetic, and tolerability data would be more defensible.

When does Brexafemme lose exclusivity?

Brexafemme does not face biosimilar competition because ibrexafungerp is a small-molecule drug. The principal future threat is generic competition under the Abbreviated New Drug Application pathway.

The key exclusivity periods are:

Exclusivity or protection	Status
New chemical entity exclusivity	Five years from FDA approval, subject to statutory limitations
Original FDA approval	May 2021
Recurrent VVC approval	December 2022
Pediatric exclusivity	Adds six months only if FDA requirements and conditions are satisfied
Orange Book patents	Governed by the patents listed for the approved NDA
Formulation patents	Could provide later protection if a new formulation receives separate approval

The five-year new chemical entity period would have ended in 2026, assuming no applicable extension. Patent-based protection therefore becomes the primary barrier to generic entry. Brexafemme’s patent position should be assessed through the current FDA Orange Book, the relevant patent assignments, terminal disclaimers, and any Paragraph IV litigation. (FDA, 2024b)

Patent expiration dates can differ from the nominal 20-year term because of patent-term adjustment, patent-term extension, terminal disclaimers, and regulatory review calculations. A commercial analysis should distinguish between the earliest possible generic approval date and the earliest commercially viable launch date.

What is the Orange Book status of Brexafemme?

Brexafemme is approved under NDA 214900 and is subject to the FDA’s Orange Book framework for listed patents and exclusivity. Orange Book-listed patents can create certification obligations for generic applicants and may trigger a 30-month stay if the sponsor files timely patent litigation after receiving a Paragraph IV notice.

The principal legal questions are:

1. Which patents are currently listed against NDA 214900?
2. Are the listed patents directed to the active ingredient, formulation, method of treatment, or drug product?
3. Which claims cover the approved recurrent-VVC regimen?
4. Are the patents expiring before or after the core commercial opportunity in recurrent VVC?
5. Has SCYNEXIS obtained pediatric exclusivity or patent-term extension?
6. Have any generic applicants filed Paragraph IV certifications?

A formulation reformulation is unlikely to block generic versions of the existing tablet unless the new product becomes the commercially dominant presentation and the sponsor obtains enforceable patents covering the marketed formulation.

Which companies are challenging Brexafemme?

The relevant competitive set includes generic manufacturers, azole suppliers, and developers of alternative antifungal products. Publicly visible competitive pressure is more likely to emerge from generic fluconazole and other oral azoles than from a direct ibrexafungerp generic in the near term.

Potential generic entrants would evaluate:

• Ibrexafungerp active-ingredient patents
• Tablet composition and manufacturing patents
• Method-of-use patents for recurrent VVC
• FDA requirements for bioequivalence under fed conditions
• Food-effect studies
• Drug-drug interaction requirements
• Market size and reimbursement
• The cost of obtaining a Paragraph IV launch position

A generic applicant can challenge method-of-use patents through a Section viii statement if it can carve out protected indications from labeling. That strategy becomes more difficult if the recurrent-VVC indication is commercially important and the sponsor has broad or overlapping method claims.

What excipient strategies have the strongest commercial potential?

1. Food-independent immediate-release tablet

This is the most commercially direct opportunity. A formulation that produces equivalent exposure in fasted and fed states could remove a key administration instruction and simplify prescribing.

Commercial advantages include:

• Easier patient counseling
• Better adherence
• Lower risk of incorrect administration
• Greater suitability for urgent treatment
• Potential use in settings where food intake is uncertain

The product would need comparative pharmacokinetic data showing that the new formulation does not materially alter efficacy or safety.

2. 300 mg unit-dose tablet

A single-tablet regimen could simplify treatment and reduce packaging costs. The principal technical barriers are tablet mass, dose uniformity, mechanical strength, dissolution, and swallowability.

A unit-dose tablet also could support differentiated packaging, including a single blister for acute treatment or monthly preventive dosing.

3. Pediatric-friendly dosage form

Brexafemme is not a biologic and does not require biosimilar development, but pediatric formulation work could open an underserved segment. Potential presentations include:

• Powder for oral suspension
• Dispersible tablet
• Mini-tablet
• Granules for reconstitution

Pediatric development would require age-appropriate excipient selection, palatability testing, dose flexibility, microbial control, and stability after reconstitution. Certain excipients may face pediatric restrictions based on age and exposure. This pathway could support pediatric exclusivity if the sponsor satisfies an FDA Written Request. (FDA, 2024c)

4. Lower-cost manufacturing platform

A robust direct-compression or dry-granulation process could improve gross margin and reduce supply-chain risk. Excipient selection should prioritize:

• Consistent flow
• Low lubricant sensitivity
• Low moisture uptake
• Compression at moderate force
• Stable dissolution after scale-up
• Compatibility with high-speed tableting

A formulation that requires specialized lipid processing, spray drying, or nanomilling may offer stronger intellectual-property differentiation but impose higher manufacturing costs.

5. Alternate vaginal delivery

A vaginal tablet, gel, film, or bioadhesive system could provide local antifungal exposure with lower systemic exposure. This approach would not be a simple excipient substitution. It would require a new dosage form, local safety program, clinical efficacy studies, and likely a supplemental or separate regulatory pathway.

The commercial rationale is strongest for patients who cannot tolerate oral therapy or who prefer local treatment. The development risk is higher than for an improved oral tablet.

How does Brexafemme compare with competing antifungal products?

Product	Active ingredient	Route	Typical commercial strength	Excipient opportunity
Brexafemme	Ibrexafungerp	Oral tablet	Non-azole mechanism and recurrent-VVC indication	Fasted-state formulation, unit-dose tablet, pediatric dosage form
Diflucan and generic fluconazole	Fluconazole	Oral and other dosage forms	Low cost and broad generic availability	Limited differentiation through excipients
Terconazole	Terconazole	Vaginal	Local delivery and established use	Bioadhesive and sustained-release systems
Boric acid products	Boric acid	Vaginal	Compounded or consumer-accessible alternatives	Packaging, tolerability, and controlled delivery
Oteseconazole	Oteseconazole	Oral	Recurrent-VVC prevention with restricted patient population	Dose simplification and tolerability improvements

Ibrexafungerp’s main commercial differentiation is its non-azole mechanism. Its main formulation disadvantage is the food-related dosing instruction and two-tablet administration schedule. Excipient development should target those limitations rather than attempt broad reformulation without a clear clinical endpoint.

What patent litigation and settlement risks affect Brexafemme?

Generic litigation risk will depend on the scope and remaining term of the Orange Book-listed patents. The most important risk points are:

• Paragraph IV certification against active-ingredient or formulation patents
• Claims covering recurrent-VVC prevention
• Patent-term calculations
• A possible 30-month stay after litigation
• At-risk generic launch before final judgment
• Settlement terms involving launch dates, authorized generic rights, or license fees
• Whether a generic can carve out the recurrent-VVC indication

A settlement could preserve branded revenue while permitting an agreed generic entry date. It could also include an authorized generic arrangement that reduces price erosion but transfers volume to the sponsor’s generic channel.

What revenue exposure does the excipient strategy address?

The recurrent-VVC indication creates recurring monthly demand, making adherence and convenience more important than in a one-time treatment course. A formulation improvement could protect or expand revenue by:

• Increasing persistence over six monthly doses
• Reducing treatment abandonment
• Supporting higher net pricing through differentiated value
• Extending use into pediatric or special-population segments
• Creating a new patent estate
• Delaying substitution if the improved product gains separate market authorization

The highest-value product concept is a food-independent, single 300 mg tablet with comparable or improved tolerability. A pediatric suspension is a secondary opportunity. Vaginal delivery has potentially greater differentiation but also carries the highest clinical and regulatory cost.

Key Takeaways

• Brexafemme is an oral ibrexafungerp tablet approved for vulvovaginal candidiasis and recurrent-VVC reduction.
• Its current food requirement and two-tablet regimen create the clearest excipient-led commercial opportunities.
• A fasted-state formulation has greater near-term value than a cosmetic excipient change.
• A 300 mg unit-dose tablet could improve adherence and simplify monthly recurrent-VVC treatment.
• Pediatric-friendly formulations could support new indications and potential pediatric exclusivity.
• Generic, rather than biosimilar, competition is the relevant long-term threat.
• Orange Book patents, Paragraph IV activity, and method-of-use claim scope determine generic launch risk.
• A patentable formulation should be linked to demonstrated pharmacokinetic, dissolution, tolerability, or adherence benefits.
• Lipid systems, solid dispersions, and particle-engineered formulations are technically plausible but must be balanced against manufacturing cost.
• A vaginal dosage form offers differentiation but requires a substantially broader development program.

FAQs

Can Brexafemme be reformulated without changing its FDA approval?

Material changes to excipients, manufacturing, dosage strength, dissolution, or pharmacokinetics may require a supplement to the NDA or a new regulatory filing. The regulatory pathway depends on the extent of the change and whether the formulation remains pharmaceutically equivalent.

Would a food-independent Brexafemme tablet qualify for separate market exclusivity?

Potentially, if the sponsor obtains an approved formulation with qualifying patent claims or statutory exclusivity. Approval alone does not automatically create a new exclusivity period.

Is ibrexafungerp suitable for a liquid oral suspension?

Ibrexafungerp could be evaluated in a suspension, but insolubility, dose uniformity, physical stability, palatability, redispersibility, and preservative compatibility would be critical development issues.

Could a generic company avoid Brexafemme method-of-use patents?

A generic applicant may attempt a Section viii labeling carve-out for protected indications. The feasibility depends on the wording of the listed claims and whether the remaining unprotected uses support a viable product label.

What is the most valuable Brexafemme lifecycle-management product?

The strongest commercial candidate is a single 300 mg tablet that provides reliable exposure without requiring food, while maintaining or improving tolerability and dissolution performance.

References

1. U.S. Food and Drug Administration. (2021). Brexafemme prescribing information: Ibrexafungerp tablets, for oral use. FDA.

2. U.S. Food and Drug Administration. (2022). FDA approves new drug for recurrent vulvovaginal candidiasis. FDA.

3. U.S. Food and Drug Administration. (2024a). Brexafemme prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2024c). Pediatric exclusivity and Written Requests. FDA.

6. SCYNEXIS, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.